Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review)

Area of Science:

• Oncology
• Radiation Oncology
• Molecular Biology

Background:

• Ionizing radiation induces DNA damage, activating cellular repair pathways like NHEJ, HR, and BER.
• Poly (ADP-ribose) polymerase inhibitors (PARPi) can act as radiosensitizers by interfering with DNA repair mechanisms, particularly BER.
• This interference increases DNA damage and cell death, making PARPi a promising radiosensitizing agent.

Purpose of the Study:

• To review current evidence on the combined use of PARPi and radiotherapy (RT) in prostate cancer (PCa).
• To provide future insights into this oncological strategy for PCa treatment.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of the mechanistic rationale for PARPi and RT combination therapy.
• Evaluation of efficacy and safety data in prostate cancer.

Main Results:

• PARPi and RT combination demonstrates radiosensitizing effects in various tumors.
• Evidence in prostate cancer is primarily from preclinical studies, with an ongoing clinical trial.
• The combination therapy shows potential as a potent oncological strategy.

Conclusions:

• The combination of PARPi and radiotherapy is a promising strategy for prostate cancer treatment.
• Further clinical investigation is warranted to establish its role in PCa management.
• Understanding the interplay between PARPi, RT, and DNA repair pathways is crucial for optimizing treatment outcomes.